Keiko Kamei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Keiko Kamei has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
- Ippei Matsumoto
Department of Surgery Kindai University Faculty of Medicine Osakasayama Japan
8 shared publications - Atsushi Takebe
Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Sakai, Osaka, Japan
3 shared publications - Takaaki Murase
Department of Surgery, Kindai University Faculty of Medicine, 1-14-1 Mihara-dai, Minami-ku, Sakai, Osaka 590-0197, Japan
3 shared publications - Yuta Yoshida
Department of Surgery, Kindai University Faculty of Medicine, Osakasayama, Japan
3 shared publications - Akimasa Nakao
Department of Gastroenterological Surgery, Nagoya Central Hospital, Nakamura-ku, Nagoya, Aichi, Japan
2 shared publications - Chihoko Nobori
Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Sakai, Osaka, Japan
2 shared publications
Latest Publications
- 12 April 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (7) , 904-909
Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geriatric patients: JCOG2101C (PRESTIGE study)
Neoadjuvant gemcitabine plus S-1 (GS) followed by surgery and adjuvant S-1 is the standard of care for resectable pancreatic cancer. Since ~73% of newly diagnosed pancreatic cancer patients are aged ≥70, effective treatments are strongly needed in this geriatric population. In unresectable pancreatic cancer, gemcitabine plus nab-paclitaxel (GnP) is widely used, even among geriatric patients. To evaluate the survival advantage of neoadjuvant GnP over GS for geriatric patients with resectable pancreatic cancer, an open-label randomized phase III trial (JCOG2101C) has been initiated since October 2022. A total of 400 patients will be enrolled from 28 institutions within 3 years. The primary endpoint is overall survival. This trial was registered at the Japan Registry of Clinical Trials as jRCTs031220351 [https://jrct.mhlw.go.jp/latest-detail/jRCTs031220351].
- 12 April 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (7) , 904-909
Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geriatric patients: JCOG2101C (PRESTIGE study)
Neoadjuvant gemcitabine plus S-1 (GS) followed by surgery and adjuvant S-1 is the standard of care for resectable pancreatic cancer. Since ~73% of newly diagnosed pancreatic cancer patients are aged ≥70, effective treatments are strongly needed in this geriatric population. In unresectable pancreatic cancer, gemcitabine plus nab-paclitaxel (GnP) is widely used, even among geriatric patients. To evaluate the survival advantage of neoadjuvant GnP over GS for geriatric patients with resectable pancreatic cancer, an open-label randomized phase III trial (JCOG2101C) has been initiated since October 2022. A total of 400 patients will be enrolled from 28 institutions within 3 years. The primary endpoint is overall survival. This trial was registered at the Japan Registry of Clinical Trials as jRCTs031220351 [https://jrct.mhlw.go.jp/latest-detail/jRCTs031220351].
- Open Access
- 5 March 2026
- Published by S. Karger AG in Liver Cancer
- p. 1-18
Clinical Prediction of Glycolysis-Driven Molecular Subclass of Hepatocellular Carcinoma without Transcriptomic Profiling
Introduction: Glycolysis-driven hepatocellular carcinoma (HCC) has been associated with resistance to immune checkpoint inhibitors; however, clinical implementation of glycolysis-targeted therapies remains limited by the reliance on transcriptomic subclassification. Methods: We developed a logistic regression model using clinical and pathological features to predict transcriptome-defined glycolysis subclass (training cohort, n = 113). An integer-based scoring system was derived for bedside application. Model performance was assessed using classification metrics, with external validation in TCGA-LIHC cohort. Imaging correlations were analyzed with 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) and magnetic resonance imaging (MRI) in a clinical cohort (n = 133) lacking transcriptomic data. In addition, pathology-free LASSO model was also developed using 18F-FDG PET/CT, contrast-enhanced CT/Gd-MRI, and serum biomarkers. Results: The integer logistic model (cutoff ≥3), incorporating serum α-fetoprotein, serum albumin, arterial enhancement pattern, and histopathological phenotypes (macrotrabecular-massive, compact, and pseudoglandular), achieved an area under the receiver operating characteristic curve (AUROC) of 0.905, accuracy of 0.850, and F1 score of 0.80 in the training cohort, with consistent performance across subgroups. External validation using the fully annotated subset of the TCGA-LIHC cohort (n = 70) demonstrated preserved model performance (AUROC = 0.825). When applied to the clinical cohort, predicted glycolysis-enhanced HCCs demonstrated significantly higher 18F-FDG uptake and distinct hepatobiliary phase defect on Gd-EOB-DTPA-enhanced MRI. Patients classified as the glycolysis subclass showed a trend toward shorter overall survival (median 95 months, p = 0.079) and significantly shorter recurrence-free survival (median 14.4 vs. 37.7 months, p = 0.017). Visual 18F-FDG PET positivity was strongly associated with the glycolysis subclass (p < 0.001) and corresponded to a tumor-to-liver uptake ratio ≥1.51. A pathology-free LASSO model using four non-invasive variables demonstrated robust predictive performance (AUROC = 0.893). Elevated glycolytic activity was exploratively correlated with lower CD8+ T-cell infiltration and increased PD-1+CTLA-4+CD8+ T cells. Conclusion: We provide a transcriptomics-independent logistic regression model for identifying glycolysis-enhanced HCC. This approach enables practical metabolic subclassification of HCC using routinely available clinical data. Macrotrabecular-massive and compact histopathological patterns, inhomogeneous arterial hyperenhancement, elevated serum α-fetoprotein levels, and 18F-FDG PET positivity are characteristic features of this subclass and may serve as potential indicators to inform the applicability of glycolysis-targeting therapies.
- 5 March 2026
- Published by S. Karger AG in Liver Cancer
- p. 1-18
Open AccessClinical Prediction of Glycolysis-Driven Molecular Subclass of Hepatocellular Carcinoma without Transcriptomic Profiling
Introduction: Glycolysis-driven hepatocellular carcinoma (HCC) has been associated with resistance to immune checkpoint inhibitors; however, clinical implementation of glycolysis-targeted therapies remains limited by the reliance on transcriptomic subclassification. Methods: We developed a logistic regression model using clinical and pathological features to predict transcriptome-defined glycolysis subclass (training cohort, n = 113). An integer-based scoring system was derived for bedside application. Model performance was assessed using classification metrics, with external validation in TCGA-LIHC cohort. Imaging correlations were analyzed with 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) and magnetic resonance imaging (MRI) in a clinical cohort (n = 133) lacking transcriptomic data. In addition, pathology-free LASSO model was also developed using 18F-FDG PET/CT, contrast-enhanced CT/Gd-MRI, and serum biomarkers. Results: The integer logistic model (cutoff ≥3), incorporating serum α-fetoprotein, serum albumin, arterial enhancement pattern, and histopathological phenotypes (macrotrabecular-massive, compact, and pseudoglandular), achieved an area under the receiver operating characteristic curve (AUROC) of 0.905, accuracy of 0.850, and F1 score of 0.80 in the training cohort, with consistent performance across subgroups. External validation using the fully annotated subset of the TCGA-LIHC cohort (n = 70) demonstrated preserved model performance (AUROC = 0.825). When applied to the clinical cohort, predicted glycolysis-enhanced HCCs demonstrated significantly higher 18F-FDG uptake and distinct hepatobiliary phase defect on Gd-EOB-DTPA-enhanced MRI. Patients classified as the glycolysis subclass showed a trend toward shorter overall survival (median 95 months, p = 0.079) and significantly shorter recurrence-free survival (median 14.4 vs. 37.7 months, p = 0.017). Visual 18F-FDG PET positivity was strongly associated with the glycolysis subclass (p < 0.001) and corresponded to a tumor-to-liver uptake ratio ≥1.51. A pathology-free LASSO model using four non-invasive variables demonstrated robust predictive performance (AUROC = 0.893). Elevated glycolytic activity was exploratively correlated with lower CD8+ T-cell infiltration and increased PD-1+CTLA-4+CD8+ T cells. Conclusion: We provide a transcriptomics-independent logistic regression model for identifying glycolysis-enhanced HCC. This approach enables practical metabolic subclassification of HCC using routinely available clinical data. Macrotrabecular-massive and compact histopathological patterns, inhomogeneous arterial hyperenhancement, elevated serum α-fetoprotein levels, and 18F-FDG PET positivity are characteristic features of this subclass and may serve as potential indicators to inform the applicability of glycolysis-targeting therapies.
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1)
Pancreatic Ischemic Necrosis Caused by Cholesterol Crystal Embolization Following Total Arch Replacement: A Case Report
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1)
Pancreatic Ischemic Necrosis Caused by Cholesterol Crystal Embolization Following Total Arch Replacement: A Case Report
- Open Access
- 7 August 2025
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 283 (4) , 581-592
Mesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial)
Objective: This multicenter randomized controlled trial investigated whether the mesenteric approach, which is an infracolic superior mesenteric artery (SMA)-first approach during pancreatoduodenectomy (PD), can improve survival in patients with pancreatic ductal adenocarcinoma (PDAC), compared with the Kocher-first conventional approach. Background: The mesenteric approach might improve surgical outcomes through a nontouch isolation technique for PDAC. Methods: This trial was conducted in 24 Japanese high-volume centers. Patients who were scheduled to undergo PD for resectable PDAC or borderline resectable PDAC with portal vein invasion (BR-PV PDAC) were randomly assigned (1:1) via a central web-based application to the conventional or mesenteric approach. The primary endpoint was overall survival (OS). We also analyzed circulating tumor cell (CTC) DNA in the PV blood obtained during surgery. This trial is registered with ClinicalTrials.gov. NCT03317886, and UMIN Clinical Trials UMIN000029615. Results: Between 2018 and 2021, 360 patients were randomly assigned to conventional (n=181) and mesenteric groups (n=179). With a median follow-up of 39.3 months, the median OS was comparable between conventional and mesenteric groups (41.7 vs. 39.3 months; HR 1.02, 95% CI: 0.76–1.37, P =0.897). CTC analysis showed that the mean change in CTC DNA copy number in PV obtained at laparotomy and just before removal of the specimen was significantly different between the conventional (10.1±2.7) and mesenteric (−7.3±2.6) groups ( P <0.001). Conclusions: The mesenteric approach does not improve survival in patients with resectable or BR-PV PDAC, although it might prevent spread of cancer cells via vessels during surgery through the nontouch isolation procedure.
- 7 August 2025
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 283 (4) , 581-592
Open AccessMesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial)
Objective: This multicenter randomized controlled trial investigated whether the mesenteric approach, which is an infracolic superior mesenteric artery (SMA)-first approach during pancreatoduodenectomy (PD), can improve survival in patients with pancreatic ductal adenocarcinoma (PDAC), compared with the Kocher-first conventional approach. Background: The mesenteric approach might improve surgical outcomes through a nontouch isolation technique for PDAC. Methods: This trial was conducted in 24 Japanese high-volume centers. Patients who were scheduled to undergo PD for resectable PDAC or borderline resectable PDAC with portal vein invasion (BR-PV PDAC) were randomly assigned (1:1) via a central web-based application to the conventional or mesenteric approach. The primary endpoint was overall survival (OS). We also analyzed circulating tumor cell (CTC) DNA in the PV blood obtained during surgery. This trial is registered with ClinicalTrials.gov. NCT03317886, and UMIN Clinical Trials UMIN000029615. Results: Between 2018 and 2021, 360 patients were randomly assigned to conventional (n=181) and mesenteric groups (n=179). With a median follow-up of 39.3 months, the median OS was comparable between conventional and mesenteric groups (41.7 vs. 39.3 months; HR 1.02, 95% CI: 0.76–1.37, P =0.897). CTC analysis showed that the mean change in CTC DNA copy number in PV obtained at laparotomy and just before removal of the specimen was significantly different between the conventional (10.1±2.7) and mesenteric (−7.3±2.6) groups ( P <0.001). Conclusions: The mesenteric approach does not improve survival in patients with resectable or BR-PV PDAC, although it might prevent spread of cancer cells via vessels during surgery through the nontouch isolation procedure.
- Open Access
- 1 January 2025
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 11 (1) , cr.24-0058
An Extremely Rare Case of Coexisting Neuroendocrine Carcinoma and Tumor of the Whole Pancreas with Hepatoid Differentiation
INTRODUCTION: Hepatoid carcinoma (HC) is a rare type of malignant tumor that shares similar serological, morphological, and immunohistochemical features with hepatocellular carcinoma. Pancreatic HC exhibits aggressive biological behavior and is classified as pure type, combined type, and mixed type. Unlike the pure type, the combined and mixed types refer to HC with other histological components. While the most common component is the neuroendocrine tumor (NET), no case of coexistence of neuroendocrine carcinoma (NEC) and NET with hepatoid differentiation has been reported. We herein report an extremely rare case of coexisting NEC and NET of the whole pancreas with hepatoid differentiation.CASE PRESENTATION: A 15-year-old woman had epigastric pain and impaired glucose tolerance, without any medical or family history. Computed tomography (CT) revealed a 6.4-cm mass in the pancreatic head, an enhanced mass throughout the pancreas, and a 1.0-cm liver lesion. Positron emission tomography (PET)/CT and somatostatin receptor scintigraphy (SRS) suggested a NET in the pancreatic body and tail, and a NEC in the pancreatic head. Biopsies confirmed NEC in the pancreatic head and liver with possible hepatoid differentiation. The patient underwent combination chemotherapy with carboplatin and etoposide. Due to the partial response achieved with chemotherapy, which led to significant tumor shrinkage on CT and no uptake on PET/CT in the pancreatic head tumor, the patient proceeded with conversion surgery, including a total pancreatectomy with portal vein resection and partial hepatectomy. However, serum α-fetoprotein (AFP) levels rapidly rose, and multiple liver metastases of NEC were detected on CT at 5 months after surgery. Liver metastases worsened despite further chemotherapy. The patient died 10 months after surgery.CONCLUSIONS: We herein present an extremely rare case of coexisting NET and NEC of the whole pancreas with hepatoid differentiation. Due to a remarkable response to chemotherapy, conversion surgery was performed. However, early recurrence of liver metastases accompanied by a rapid increase in serum AFP levels occurred, and the prognosis was poor. Pancreatic HC should be considered when encountering a bulky tumor of the pancreas with elevated serum AFP levels, and further case series and analysis are needed to determine the appropriate treatment strategy.
- 1 January 2025
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 11 (1) , cr.24-0058
Open AccessAn Extremely Rare Case of Coexisting Neuroendocrine Carcinoma and Tumor of the Whole Pancreas with Hepatoid Differentiation
INTRODUCTION: Hepatoid carcinoma (HC) is a rare type of malignant tumor that shares similar serological, morphological, and immunohistochemical features with hepatocellular carcinoma. Pancreatic HC exhibits aggressive biological behavior and is classified as pure type, combined type, and mixed type. Unlike the pure type, the combined and mixed types refer to HC with other histological components. While the most common component is the neuroendocrine tumor (NET), no case of coexistence of neuroendocrine carcinoma (NEC) and NET with hepatoid differentiation has been reported. We herein report an extremely rare case of coexisting NEC and NET of the whole pancreas with hepatoid differentiation.CASE PRESENTATION: A 15-year-old woman had epigastric pain and impaired glucose tolerance, without any medical or family history. Computed tomography (CT) revealed a 6.4-cm mass in the pancreatic head, an enhanced mass throughout the pancreas, and a 1.0-cm liver lesion. Positron emission tomography (PET)/CT and somatostatin receptor scintigraphy (SRS) suggested a NET in the pancreatic body and tail, and a NEC in the pancreatic head. Biopsies confirmed NEC in the pancreatic head and liver with possible hepatoid differentiation. The patient underwent combination chemotherapy with carboplatin and etoposide. Due to the partial response achieved with chemotherapy, which led to significant tumor shrinkage on CT and no uptake on PET/CT in the pancreatic head tumor, the patient proceeded with conversion surgery, including a total pancreatectomy with portal vein resection and partial hepatectomy. However, serum α-fetoprotein (AFP) levels rapidly rose, and multiple liver metastases of NEC were detected on CT at 5 months after surgery. Liver metastases worsened despite further chemotherapy. The patient died 10 months after surgery.CONCLUSIONS: We herein present an extremely rare case of coexisting NET and NEC of the whole pancreas with hepatoid differentiation. Due to a remarkable response to chemotherapy, conversion surgery was performed. However, early recurrence of liver metastases accompanied by a rapid increase in serum AFP levels occurred, and the prognosis was poor. Pancreatic HC should be considered when encountering a bulky tumor of the pancreas with elevated serum AFP levels, and further case series and analysis are needed to determine the appropriate treatment strategy.
- Open Access
- 27 October 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (3) , 619-630
High Incidence of Diabetes Mellitus After Distal Pancreatectomy and Its Predictors: A Long-term Follow-up Study
Context: Glucose tolerance worsens after distal pancreatectomy (DP); however, the long-term incidence and factors affecting interindividual variation in this worsening are unclear. Objective: To investigate the changes in diabetes-related traits before and after DP and to clarify the incidence of diabetes and its predictors. Methods: Among 493 registered patients, 117 underwent DP. Among these, 56 patients without diabetes before surgery were included in the study. Glucose and endocrine function were prospectively assessed using a 75-g oral glucose tolerance test preoperatively, 1 month after DP, and every 6 months thereafter for up to 36 months. Pancreatic volumetry was performed using multidetector row computed tomography before and after surgery. Results: Insulin secretion decreased and blood glucose levels worsened after DP. Residual pancreatic volume was significantly associated with the reserve capacity of insulin secretion but not with blood glucose levels or the development of diabetes. Among 56 patients, 33 developed diabetes mellitus. The cumulative incidence of diabetes at 36 months after DP was 74.1%. Multivariate Cox regression analysis showed that impaired glucose tolerance as a preoperative factor as well as a decreased insulinogenic index and impaired glucose tolerance at 1 month postoperatively were identified as risk factors for diabetes following DP. Conclusion: Impaired glucose tolerance and reduced early-phase insulin response to glucose are involved in the development of new-onset diabetes after DP; the latter is an additional factor in the development of diabetes and becomes apparent when pancreatic beta cell mass is reduced after DP.
- 27 October 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (3) , 619-630
Open AccessHigh Incidence of Diabetes Mellitus After Distal Pancreatectomy and Its Predictors: A Long-term Follow-up Study
Context: Glucose tolerance worsens after distal pancreatectomy (DP); however, the long-term incidence and factors affecting interindividual variation in this worsening are unclear. Objective: To investigate the changes in diabetes-related traits before and after DP and to clarify the incidence of diabetes and its predictors. Methods: Among 493 registered patients, 117 underwent DP. Among these, 56 patients without diabetes before surgery were included in the study. Glucose and endocrine function were prospectively assessed using a 75-g oral glucose tolerance test preoperatively, 1 month after DP, and every 6 months thereafter for up to 36 months. Pancreatic volumetry was performed using multidetector row computed tomography before and after surgery. Results: Insulin secretion decreased and blood glucose levels worsened after DP. Residual pancreatic volume was significantly associated with the reserve capacity of insulin secretion but not with blood glucose levels or the development of diabetes. Among 56 patients, 33 developed diabetes mellitus. The cumulative incidence of diabetes at 36 months after DP was 74.1%. Multivariate Cox regression analysis showed that impaired glucose tolerance as a preoperative factor as well as a decreased insulinogenic index and impaired glucose tolerance at 1 month postoperatively were identified as risk factors for diabetes following DP. Conclusion: Impaired glucose tolerance and reduced early-phase insulin response to glucose are involved in the development of new-onset diabetes after DP; the latter is an additional factor in the development of diabetes and becomes apparent when pancreatic beta cell mass is reduced after DP.
- Open Access
- 16 September 2021
- Published by Springer Nature in Trials
- Vol. 22 (1) , 1-9
ISOlation Procedure vs. conventional procedure during Distal Pancreatectomy (ISOP-DP trial): study protocol for a randomized controlled trial
Background: Radical antegrade modular pancreatosplenectomy (RAMPS) is an isolation procedure in pancreatosplenectomy for pancreatic body/tail cancer. Connective tissues around the bifurcation of the celiac axis are dissected, followed by median-to-left retroperitoneal dissection. This procedure has the potential to isolate blood and lymphatic flow to the area of the pancreatic body/tail and the spleen to be excised. This is achieved by division of the inflow artery, transection of the pancreas, and then division of the outflow vein in the early phases of surgery. In cases of pancreatic ductal adenocarcinoma (PDAC), the procedure has been shown to decrease intraoperative blood loss and increase R0 resection rate by complete clearance of the lymph nodes. This trial investigates whether the isolation procedure can prolong the survival of patients with pancreatic ductal adenocarcinoma who undergo distal pancreatosplenectomy (DPS) compared with those that undergo the conventional approach. Methods/design: Patients with PDAC scheduled to undergo DPS are randomized before surgery to undergo either a conventional procedure (arm A) or to undergo the isolation procedure (arm B). In arm A, the pancreatic body, tail, and spleen are mobilized, followed by removal of the regional lymph nodes. The splenic vein is transected at the end of the procedure. The timing of division of the splenic artery (SA) is not restricted. In arm B, regional lymph nodes are dissected, then we transect the root of the SA, the pancreas, then the splenic vein. At the end of the procedure, the pancreatic body/tail and spleen are mobilized and removed. In total, 100 patients from multiple Japanese high-volume centers will be randomized. The primary endpoint is 2-year recurrence-free survival by intention-to-treat analysis. Secondary endpoints include intraoperative blood loss, R0 resection rate, and overall survival. Discussion: If this trial shows that the isolation procedures can improve survival with a similar R0 rate and with a similar number of lymph node dissections to the conventional procedure, the isolation procedure is expected to become a standard procedure during DPS for PDAC. Conversely, if there were no significant differences in endpoints between the groups, it would demonstrate justification of either procedure from surgical and oncological points of view. Trial registration: UMIN Clinical Trials Registry UMIN000041381. Registered on 10 August 2020. ClinicalTrials.gov NCT04600063. Registered on 22 October 2020.
- 16 September 2021
- Published by Springer Nature in Trials
- Vol. 22 (1) , 1-9
Open AccessISOlation Procedure vs. conventional procedure during Distal Pancreatectomy (ISOP-DP trial): study protocol for a randomized controlled trial
Background: Radical antegrade modular pancreatosplenectomy (RAMPS) is an isolation procedure in pancreatosplenectomy for pancreatic body/tail cancer. Connective tissues around the bifurcation of the celiac axis are dissected, followed by median-to-left retroperitoneal dissection. This procedure has the potential to isolate blood and lymphatic flow to the area of the pancreatic body/tail and the spleen to be excised. This is achieved by division of the inflow artery, transection of the pancreas, and then division of the outflow vein in the early phases of surgery. In cases of pancreatic ductal adenocarcinoma (PDAC), the procedure has been shown to decrease intraoperative blood loss and increase R0 resection rate by complete clearance of the lymph nodes. This trial investigates whether the isolation procedure can prolong the survival of patients with pancreatic ductal adenocarcinoma who undergo distal pancreatosplenectomy (DPS) compared with those that undergo the conventional approach. Methods/design: Patients with PDAC scheduled to undergo DPS are randomized before surgery to undergo either a conventional procedure (arm A) or to undergo the isolation procedure (arm B). In arm A, the pancreatic body, tail, and spleen are mobilized, followed by removal of the regional lymph nodes. The splenic vein is transected at the end of the procedure. The timing of division of the splenic artery (SA) is not restricted. In arm B, regional lymph nodes are dissected, then we transect the root of the SA, the pancreas, then the splenic vein. At the end of the procedure, the pancreatic body/tail and spleen are mobilized and removed. In total, 100 patients from multiple Japanese high-volume centers will be randomized. The primary endpoint is 2-year recurrence-free survival by intention-to-treat analysis. Secondary endpoints include intraoperative blood loss, R0 resection rate, and overall survival. Discussion: If this trial shows that the isolation procedures can improve survival with a similar R0 rate and with a similar number of lymph node dissections to the conventional procedure, the isolation procedure is expected to become a standard procedure during DPS for PDAC. Conversely, if there were no significant differences in endpoints between the groups, it would demonstrate justification of either procedure from surgical and oncological points of view. Trial registration: UMIN Clinical Trials Registry UMIN000041381. Registered on 10 August 2020. ClinicalTrials.gov NCT04600063. Registered on 22 October 2020.
- Open Access
- 22 April 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (9) , 1818
Should Contrast-Enhanced Harmonic Endoscopic Ultrasound Be Incorporated into the International Consensus Guidelines to Determine the Appropriate Treatment of Intraductal Papillary Mucinous Neoplasm?
This study aimed to investigate whether the incorporation of contrast-enhanced harmonic endoscopic ultrasound (CH-EUS) into the international consensus guidelines (ICG) for the management of intraductal papillary mucinous neoplasm (IPMN) could improve its malignancy diagnostic value. In this single-center retrospective study, 109 patients diagnosed with IPMN who underwent preoperative CH-EUS between March 2010 and December 2018 were enrolled. We analyzed each malignancy diagnostic value (sensitivity (Se), specificity (Sp), positive predictive value (PPV), and negative predictive value (NPV)) by replacing fundamental B-mode EUS with CH-EUS as the recommended test for patients with worrisome features (WF) (the CH-EUS incorporation ICG) and comparing the results to those obtained using the 2017 ICG. The malignancy diagnostic values as per the 2017 ICG were 78.9%, 42.3%, 60.0%, and 64.7% for Se, Sp, PPV, and NPV, respectively. The CH-EUS incorporation ICG plan improved the malignancy diagnostic values (Se 78.9%/Sp, 53.8%/PPV, 65.2%/NPV 70.0%). CH-EUS may be useful in determining the appropriate treatment strategies for IPMN.
- 22 April 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (9) , 1818
Open AccessShould Contrast-Enhanced Harmonic Endoscopic Ultrasound Be Incorporated into the International Consensus Guidelines to Determine the Appropriate Treatment of Intraductal Papillary Mucinous Neoplasm?
This study aimed to investigate whether the incorporation of contrast-enhanced harmonic endoscopic ultrasound (CH-EUS) into the international consensus guidelines (ICG) for the management of intraductal papillary mucinous neoplasm (IPMN) could improve its malignancy diagnostic value. In this single-center retrospective study, 109 patients diagnosed with IPMN who underwent preoperative CH-EUS between March 2010 and December 2018 were enrolled. We analyzed each malignancy diagnostic value (sensitivity (Se), specificity (Sp), positive predictive value (PPV), and negative predictive value (NPV)) by replacing fundamental B-mode EUS with CH-EUS as the recommended test for patients with worrisome features (WF) (the CH-EUS incorporation ICG) and comparing the results to those obtained using the 2017 ICG. The malignancy diagnostic values as per the 2017 ICG were 78.9%, 42.3%, 60.0%, and 64.7% for Se, Sp, PPV, and NPV, respectively. The CH-EUS incorporation ICG plan improved the malignancy diagnostic values (Se 78.9%/Sp, 53.8%/PPV, 65.2%/NPV 70.0%). CH-EUS may be useful in determining the appropriate treatment strategies for IPMN.
- 1 October 2020
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 16 (5) , E257-E262
A new monitoring tool CLIP test for progression of oxaliplatin-induced peripheral neuropathy: A multicenter prospective study
Introduction Oxaliplatin-induced peripheral neuropathy (OIPN) is a common adverse events that can limit a patient's quality of life during/after chemotherapy. However, no appropriate methods have been established yet for monitoring the risk of progression of OIPN. Methods A simple assessment tool using gem clips, the CLIP test, was established and its performance in predicting the risk of progression to >= grade 2 peripheral sensory neuropathy (CTCAE ver. 4.0) was investigated in patients receiving chemotherapy with oxaliplatin. Results Among 101 patients included in this study, 71 patients developed CTCAE >= grade 1 peripheral neuropathy (grade 1,n= 67; grade 2,n= 4) at a median of 63 (range, 14-259) days after the start of treatment. Of the 67 patients with grade 1 peripheral neuropathy, 17 showed progression to >= grade 2 neuropathy after a median interval of 84 (range, 21-246) days. Of these patients, 27 showed a positive result of the CLIP test at a median of 91 (range, 14-224) days, excluding one patient who already showed a positive result of the test at the baseline. Therefore, the risk ratio for the development of CTCAE >= grade 2 peripheral neuropathy was 8.3 in the patients who showed a positive result on the CLIP test. Multivariate analysis confirmed that a positive results on the CLIP test was significantly correlated with the risk of future development of CTCAE >= grade 2 peripheral neuropathy (odds ratio, 9.37;P= 0.002). Conclusion A positive result on the CLIP test predict is predictive of the risk of progression of OIPN during chemotherapy with oxaliplatin.
- 1 October 2020
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 16 (5) , E257-E262
A new monitoring tool CLIP test for progression of oxaliplatin-induced peripheral neuropathy: A multicenter prospective study
Introduction Oxaliplatin-induced peripheral neuropathy (OIPN) is a common adverse events that can limit a patient's quality of life during/after chemotherapy. However, no appropriate methods have been established yet for monitoring the risk of progression of OIPN. Methods A simple assessment tool using gem clips, the CLIP test, was established and its performance in predicting the risk of progression to >= grade 2 peripheral sensory neuropathy (CTCAE ver. 4.0) was investigated in patients receiving chemotherapy with oxaliplatin. Results Among 101 patients included in this study, 71 patients developed CTCAE >= grade 1 peripheral neuropathy (grade 1,n= 67; grade 2,n= 4) at a median of 63 (range, 14-259) days after the start of treatment. Of the 67 patients with grade 1 peripheral neuropathy, 17 showed progression to >= grade 2 neuropathy after a median interval of 84 (range, 21-246) days. Of these patients, 27 showed a positive result of the CLIP test at a median of 91 (range, 14-224) days, excluding one patient who already showed a positive result of the test at the baseline. Therefore, the risk ratio for the development of CTCAE >= grade 2 peripheral neuropathy was 8.3 in the patients who showed a positive result on the CLIP test. Multivariate analysis confirmed that a positive results on the CLIP test was significantly correlated with the risk of future development of CTCAE >= grade 2 peripheral neuropathy (odds ratio, 9.37;P= 0.002). Conclusion A positive result on the CLIP test predict is predictive of the risk of progression of OIPN during chemotherapy with oxaliplatin.